The original FDA-approved GLP-1 agonist for weight management with over a decade of clinical data.
Liraglutide is a GLP-1 receptor agonist developed by Novo Nordisk. It was the first GLP-1 approved for both diabetes (as Victoza, 2010) and weight management (as Saxenda, 2014). Unlike semaglutide which is given weekly, liraglutide requires daily injection due to its shorter half-life.
Structurally, liraglutide is about 97% identical to human GLP-1, with a fatty acid chain attached that enables binding to albumin and extends its half-life to ~13 hours. It works through the same mechanisms as semaglutide: reducing appetite through central GLP-1 receptors, slowing gastric emptying, and improving insulin sensitivity.
With over 10 years of real-world safety data, liraglutide has one of the longest track records of any weight-loss medication. However, it generally produces less weight loss than semaglutide or tirzepatide, and daily injections are less convenient than weekly dosing. Many providers now prefer newer agents but liraglutide remains a relevant option.
The SCALE clinical trial program demonstrated approximately 8% average body weight loss over 56 weeks at the 3.0 mg dose. The LEADER trial (for diabetes/cardiovascular risk) showed a 13% reduction in major cardiovascular events — the first cardiovascular outcome trial to show GLP-1 benefit in diabetes patients.
Liraglutide is FDA-approved for weight management in children aged 12 and older with obesity — a significant distinction. Extensive pediatric and adolescent data provides a safety database that newer agents don't yet have.
📚 Key Reference: PMID: 25761324 (SCALE trial), PMID: 26378978 (LEADER trial)
Most common side effects: nausea, diarrhea, constipation, vomiting, headache. Nausea often improves with dose titration. Same thyroid cancer and pancreatitis warnings as semaglutide apply. Hypoglycemia risk when combined with other diabetes medications. Liraglutide use during pregnancy is not recommended. Discuss your full medical history with your provider.
FDA-approved as Saxenda (weight management, Novo Nordisk) and Victoza (type 2 diabetes, Novo Nordisk). Both are original FDA-approved products. Not commonly compounded. Victoza approval for cardiovascular risk reduction in adults with type 2 diabetes was added in 2017.